JP2021017402A - 軽度認知障害改善用組成物及びこの組成物を用いた軽度認知障害の改善方法 - Google Patents
軽度認知障害改善用組成物及びこの組成物を用いた軽度認知障害の改善方法 Download PDFInfo
- Publication number
- JP2021017402A JP2021017402A JP2019132196A JP2019132196A JP2021017402A JP 2021017402 A JP2021017402 A JP 2021017402A JP 2019132196 A JP2019132196 A JP 2019132196A JP 2019132196 A JP2019132196 A JP 2019132196A JP 2021017402 A JP2021017402 A JP 2021017402A
- Authority
- JP
- Japan
- Prior art keywords
- cognitive impairment
- mild cognitive
- composition
- improving
- imidazole dipeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000010877 cognitive disease Diseases 0.000 title claims abstract description 43
- 208000027061 mild cognitive impairment Diseases 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title claims description 14
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims abstract description 55
- 239000000284 extract Substances 0.000 claims abstract description 24
- 108010016626 Dipeptides Proteins 0.000 claims abstract description 20
- 108010085443 Anserine Proteins 0.000 claims abstract description 19
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 claims abstract description 19
- 241000210053 Potentilla elegans Species 0.000 claims abstract description 17
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical group CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 claims abstract description 17
- 241000972773 Aulopiformes Species 0.000 claims abstract description 11
- 235000019515 salmon Nutrition 0.000 claims abstract description 11
- 239000012535 impurity Substances 0.000 claims abstract description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- 206010012289 Dementia Diseases 0.000 claims description 15
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 9
- 241000287828 Gallus gallus Species 0.000 claims description 9
- 229930003268 Vitamin C Natural products 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 9
- 235000006708 antioxidants Nutrition 0.000 claims description 9
- 235000019154 vitamin C Nutrition 0.000 claims description 9
- 239000011718 vitamin C Substances 0.000 claims description 9
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 8
- 235000001785 ferulic acid Nutrition 0.000 claims description 8
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 8
- 229940114124 ferulic acid Drugs 0.000 claims description 8
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 8
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 8
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 4
- 235000013793 astaxanthin Nutrition 0.000 claims description 4
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 4
- 229940022405 astaxanthin Drugs 0.000 claims description 4
- 239000001168 astaxanthin Substances 0.000 claims description 4
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 3
- 108010087806 Carnosine Proteins 0.000 claims description 3
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 3
- 229940044199 carnosine Drugs 0.000 claims description 3
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical group [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- SLRNWACWRVGMKD-QMMMGPOBSA-N Balenine Chemical compound CN1C=NC(C[C@H](N=C(O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-QMMMGPOBSA-N 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 230000001149 cognitive effect Effects 0.000 claims description 2
- 238000001308 synthesis method Methods 0.000 claims description 2
- 235000013330 chicken meat Nutrition 0.000 abstract 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 32
- 229940109239 creatinine Drugs 0.000 description 16
- 230000000694 effects Effects 0.000 description 12
- 230000003078 antioxidant effect Effects 0.000 description 11
- 230000007850 degeneration Effects 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 5
- 241001112258 Moca Species 0.000 description 5
- 235000013372 meat Nutrition 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- -1 hypochlorous acid radical Chemical class 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 235000021194 placebo diet Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000006933 amyloid-beta aggregation Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000000944 nerve tissue Anatomy 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000003668 pericyte Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000002250 progressing effect Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241000723298 Dicentrarchus labrax Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020919 Hypervolaemia Diseases 0.000 description 1
- CCLQKVKJOGVQLU-QMMMGPOBSA-N L-homocarnosine Chemical compound NCCCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 CCLQKVKJOGVQLU-QMMMGPOBSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 108700002498 homocarnosine Proteins 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000008433 psychological processes and functions Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 235000021195 test diet Nutrition 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Abstract
Description
本発明に関わるIMDP標品は、図1A〜Dに示すように、鶏肉エキスまたは鮭肉エキスから、イオン交換クロマトグラフとナノろ過膜で濃縮脱塩処理されて、タンパク質、アミノ酸、クレアチニン、カリウム塩などが除去されたものを用いることとした。製造法としては例えば日本国特許5142126号の方法を使用する。
IMDPは生体内産生活性酸素種3種類(次亜塩素酸ラジカル、水酸化ラジカル、及び過酸化亜硝酸ラジカル)のうち、次亜塩素酸ラジカルに対して強い抗酸化活性を示すことが知られている。しかし、IMDPは水酸化ラジカルと過酸化亜硝酸ラジカルに対する抗酸化作用は極めて弱い。
65歳以上の中高年齢者を対象に、一次スクリーニングとして被験者の負担を軽減する観点から、試験所要時間が比較的短いMoCAを用いて行った。MoCA法ではスコアが25点以下であり、MMSEでは23点以上27点未満、またはCDRスコアでは0.5である。ちなみにCDRではスコア0は正常であり、スコア1以上は認知症を意味する。
MCIのハイリスクと判定された中高年齢者29名を対象に、二重盲検プラセボ比較試験を行った。14名には鮭エキスから精製したIMDP250mgと酸化防止剤としてフェルラ酸15mgとビタミンC75mgを含有するIMDP顆粒剤を1日2回朝夕に摂取して貰った(試験食群)。15名のプラセボ食群はIMDPの代わりにデキストラン250mgと酸化防止剤を含有するプラセボ食を同様に1日2回朝夕に摂取してもらった。3カ月摂取した後に、MoCA、MMSE、またはCDRでMCIの状態を評価した。その結果は表1に示す通り、MoCAスコアでは有意差は認められなかったが、MMSEスコアでは有意な改善効果が認められた。また、MMSEが23点以下まで低下し、臨床的認知症(Clinical Dementia,CD)が疑われる者がプラセボ食群で2名いたが、試験食群では全くみとめられなかった。
(1)イミダペプチド配合剤の製造
白鮭(セミドレス)切り身2000kgに対して水3000Lを加え、80℃、30分間加熱抽出して得られた鮭エキスをろ過し、pH5.0に調整して陽イオン交換樹脂(三菱化学、ダイアイオンSK-1B)カラムへ通液し、アンセリンをイオン交換樹脂に吸着させた後、0.5%アンモニア溶液でアンセリンを溶出させた。溶出液をNF膜(ダイセンメンブラン、Desal DL)で脱塩と濃縮を行い、クレアチニンや塩類を除去したアンセリン溶液を調製した。
Claims (4)
- 鶏肉エキスまたは鮭エキスから分離精製されたイミダゾールジペプチドを主成分とする軽度認知障害改善用組成物であって、前記イミダゾールジペプチドは生体由来不純物を含有せず、鶏肉エキス由来のイミダゾールジペプチドは75%以上がアンセリンであり、鮭エキスは由来のイミダゾールジペプチド95%以上がアンセリンであることを特徴とする軽度認知障害改善用組成物。
- 請求項1に記載の軽度認知障害改善用組成物であって、前記イミダゾールジペプチドが酵素合成法により製造される純度95%以上のカルノシンまたはアンセリンあるいはバレニンであることを特徴とする軽度認知障害改善用組成物。
- 請求項1または2に記載の軽度認知障害改善用組成物であって、前記イミダゾールジペプチドからなる組成物に、イミダゾールジペプチドの生体内酸化を抑制するために、ビタミンC、フェルラ酸、ビタミンE、またはアスタキサンチンなどから選ばれた2種以上の抗酸化剤を添加することを特徴とする軽度認知障害改善用組成物。
- ミニメンタルステータス試験で23点以上27点未満の者、臨床的認知症尺度のスコアで0.5の者、或いはモントリオール認知評価法で25点未満の軽度認知障害者に対して、請求項1〜3の何れかに記載の軽度認知障害改善用組成物250mg〜500mgを1日1〜2回、3カ月以上摂取させることを特徴とする軽度認知障害の改善法。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019132196A JP7321017B2 (ja) | 2019-07-17 | 2019-07-17 | 機能性食品 |
TW109119147A TWI801737B (zh) | 2019-07-17 | 2020-06-08 | 輕度認知障礙改善用組成物及使用該組成物之輕度認知障礙的改善方法 |
US16/931,979 US20210015886A1 (en) | 2019-07-17 | 2020-07-17 | Composition for improving mild cognitive impairment and method for improving mild cognitive impairment |
JP2023064666A JP2023080213A (ja) | 2019-07-17 | 2023-04-12 | 軽度認知障害改善用組成物 |
JP2023097266A JP2023113933A (ja) | 2019-07-17 | 2023-06-13 | 軽度認知障害改善用組成物 |
US18/360,773 US20230364180A1 (en) | 2019-07-17 | 2023-07-27 | Composition for improving mild cognitive impairment and method for improving mild cognitive impairment |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019132196A JP7321017B2 (ja) | 2019-07-17 | 2019-07-17 | 機能性食品 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023064666A Division JP2023080213A (ja) | 2019-07-17 | 2023-04-12 | 軽度認知障害改善用組成物 |
JP2023097266A Division JP2023113933A (ja) | 2019-07-17 | 2023-06-13 | 軽度認知障害改善用組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021017402A true JP2021017402A (ja) | 2021-02-15 |
JP2021017402A5 JP2021017402A5 (ja) | 2022-06-07 |
JP7321017B2 JP7321017B2 (ja) | 2023-08-04 |
Family
ID=74343267
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019132196A Active JP7321017B2 (ja) | 2019-07-17 | 2019-07-17 | 機能性食品 |
JP2023064666A Pending JP2023080213A (ja) | 2019-07-17 | 2023-04-12 | 軽度認知障害改善用組成物 |
JP2023097266A Pending JP2023113933A (ja) | 2019-07-17 | 2023-06-13 | 軽度認知障害改善用組成物 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023064666A Pending JP2023080213A (ja) | 2019-07-17 | 2023-04-12 | 軽度認知障害改善用組成物 |
JP2023097266A Pending JP2023113933A (ja) | 2019-07-17 | 2023-06-13 | 軽度認知障害改善用組成物 |
Country Status (3)
Country | Link |
---|---|
US (2) | US20210015886A1 (ja) |
JP (3) | JP7321017B2 (ja) |
TW (1) | TWI801737B (ja) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0920661A (ja) * | 1995-07-04 | 1997-01-21 | Suntory Ltd | 学習能力向上組成物 |
WO2003013514A1 (en) * | 2001-08-08 | 2003-02-20 | Carn-Aware Llc | Improving neurological functions |
JP2005336167A (ja) * | 2004-04-30 | 2005-12-08 | Japan Research & Development Association For New Functional Foods | 抗酸化性組成物 |
JP2009046451A (ja) * | 2007-08-22 | 2009-03-05 | Tokai Bussan Kk | 抗酸化性ジペプチドの製造方法 |
JP2013526518A (ja) * | 2010-05-13 | 2013-06-24 | ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション | Mciおよびアルツハイマー病の処置 |
JP2015193582A (ja) * | 2014-03-28 | 2015-11-05 | 国立大学法人 東京大学 | イミダゾールジペプチドを含む剤 |
JP2018030809A (ja) * | 2016-08-24 | 2018-03-01 | 日本ハム株式会社 | イミダゾールジペプチドを含有する、グリア細胞における神経栄養因子等の遺伝子の発現誘導剤 |
JP2018515145A (ja) * | 2015-05-18 | 2018-06-14 | エイエヌティー ラブス インコーポレイテッドAnt Labs Inc. | 初期アルツハイマー病又は軽度認知障害の診断方法 |
JP2018102287A (ja) * | 2016-12-27 | 2018-07-05 | 東海物産株式会社 | イミダゾールジペプチド合成活性を有するタンパク質及びイミダゾールジペプチドの製造方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4023648B2 (ja) * | 1999-01-13 | 2007-12-19 | 日本ハム株式会社 | 皮膚代謝促進物及び機能性食品 |
CN1313090C (zh) * | 2001-03-16 | 2007-05-02 | 三得利株式会社 | 自主神经调节剂及其保健饮食品 |
JP2007070316A (ja) * | 2005-09-09 | 2007-03-22 | Nippon Meat Packers Inc | 経口用組成物及び栄養補助食品 |
JP2014142910A (ja) * | 2012-12-28 | 2014-08-07 | Panasonic Corp | 制御装置、発電制御装置、太陽光発電システム、制御方法、及び発電制御方法 |
-
2019
- 2019-07-17 JP JP2019132196A patent/JP7321017B2/ja active Active
-
2020
- 2020-06-08 TW TW109119147A patent/TWI801737B/zh active
- 2020-07-17 US US16/931,979 patent/US20210015886A1/en active Pending
-
2023
- 2023-04-12 JP JP2023064666A patent/JP2023080213A/ja active Pending
- 2023-06-13 JP JP2023097266A patent/JP2023113933A/ja active Pending
- 2023-07-27 US US18/360,773 patent/US20230364180A1/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0920661A (ja) * | 1995-07-04 | 1997-01-21 | Suntory Ltd | 学習能力向上組成物 |
WO2003013514A1 (en) * | 2001-08-08 | 2003-02-20 | Carn-Aware Llc | Improving neurological functions |
JP2005336167A (ja) * | 2004-04-30 | 2005-12-08 | Japan Research & Development Association For New Functional Foods | 抗酸化性組成物 |
JP2009046451A (ja) * | 2007-08-22 | 2009-03-05 | Tokai Bussan Kk | 抗酸化性ジペプチドの製造方法 |
JP2013526518A (ja) * | 2010-05-13 | 2013-06-24 | ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション | Mciおよびアルツハイマー病の処置 |
JP2015193582A (ja) * | 2014-03-28 | 2015-11-05 | 国立大学法人 東京大学 | イミダゾールジペプチドを含む剤 |
JP2018515145A (ja) * | 2015-05-18 | 2018-06-14 | エイエヌティー ラブス インコーポレイテッドAnt Labs Inc. | 初期アルツハイマー病又は軽度認知障害の診断方法 |
JP2018030809A (ja) * | 2016-08-24 | 2018-03-01 | 日本ハム株式会社 | イミダゾールジペプチドを含有する、グリア細胞における神経栄養因子等の遺伝子の発現誘導剤 |
JP2018102287A (ja) * | 2016-12-27 | 2018-07-05 | 東海物産株式会社 | イミダゾールジペプチド合成活性を有するタンパク質及びイミダゾールジペプチドの製造方法 |
Non-Patent Citations (2)
Title |
---|
"日本語版MoCA 軽度認知障害スクリーニング (Instruction manual of Japanese version of Montreal Cogni", ST-MEDICA[ONLINE], JPN6023008271, March 2013 (2013-03-01), ISSN: 0005079948 * |
舛岡 伸高: "鶏肉イミダゾールジプチド摂取によるアルツハイマー病予防の可能性", 日本農芸化学会2018年度大会講演要旨集(オンライン), JPN6023008270, JP, ISSN: 0005079947 * |
Also Published As
Publication number | Publication date |
---|---|
TWI801737B (zh) | 2023-05-11 |
US20210015886A1 (en) | 2021-01-21 |
US20230364180A1 (en) | 2023-11-16 |
JP2023113933A (ja) | 2023-08-16 |
TW202116345A (zh) | 2021-05-01 |
JP2023080213A (ja) | 2023-06-08 |
JP7321017B2 (ja) | 2023-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Aliasgharpour et al. | Trace elements in human nutrition: A review | |
WO2019203136A1 (ja) | 認知機能改善用食品組成物、認知機能改善剤、及び、これらの製造方法 | |
JP7281031B2 (ja) | 加齢に伴う持続的注意力低下の改善用の組成物 | |
KR20140136915A (ko) | 세포손상 효과에 대한 보호를 제공하는 조성물 | |
JP5220415B2 (ja) | 老人性貧血を防止又は治療するためのアミノ酸組成物 | |
EP1575593A2 (de) | VERWENDUNG VON TETRAHYDROBIOPTERINDERIVATEN ZUR BEHANDLUNG UND ERN HRUNG VON PATIENTEN MIT AMINOS URESTOFFWECHSELST&Ouml ;RUNGEN | |
US20100240599A1 (en) | Antioxidant constituents | |
GB2477236A (en) | Pharmaceutical composition for preventing liver injury or improving liver function, containing activated water of ENA actimineral resource A as an ingredient | |
JP7321017B2 (ja) | 機能性食品 | |
JP4833502B2 (ja) | 抗酸化性組成物 | |
WO2016052509A1 (ja) | 腎不全進行抑制剤、腎不全予防剤及びインドキシル硫酸産生阻害剤 | |
EP3247323B1 (en) | Chlorophyll composition | |
US9737477B2 (en) | Anti-aging dietary composition containing polysaccharides derived from ginseng and tuber fleeceflower root | |
Singh et al. | Emerging role of antioxidants in Alzheimer's disease: Insight to physiological, pathological mechanisms and management | |
JP3713553B2 (ja) | アルギニンとrnaを含有する脳脊髄系神経栄養剤 | |
JP5719116B2 (ja) | 動物由来エキスを有効成分とする、老眼、老視の改善、緩和または予防のための組成物 | |
JP5749469B2 (ja) | 血圧降下剤 | |
KR102323577B1 (ko) | 부채마와 백년초의 혼합추출물을 포함하는 우울증 예방 또는 치료용 조성물 | |
TWI745609B (zh) | 具抗氧化活性之組合物 | |
RU2683311C1 (ru) | Средство для стимулирования адаптации организма к экстремальным и стрессовым факторам и способ стимулирования адаптации организма к экстремальным и стрессовым факторам | |
JP2023179383A (ja) | アミロイドβによるリン酸化タウタンパク質の増加抑制用の組成物 | |
US20210322353A1 (en) | Nutritional composition for the treatment of metabolic diseases | |
JP2022186084A (ja) | グルタチオン産生増強剤 | |
WO2016072496A1 (ja) | アルコール代謝促進剤 | |
Kyriazis | Carnosine: the new anti-aging supplement |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220530 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230302 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230412 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230608 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230613 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230621 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230724 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230725 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7321017 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |